Challenge: Proteins are the main effectors of cell activity and cardinal indicators of cell phenotype and response to stimuli such as drugs. Whereas sequencing technologies currently allow for broad and efficient genomic and transcriptomic profiling, multiplexed protein detection technologies are either prohibitively slow and expensive, limited in scope due to reagent cross-reactivity, or both. Critically, phenotypic drug screening would greatly benefit from an economically viable method of quantifying proteins in a high-throughput and high-content manner.
Solution: The Juncker lab and nplex biosciences have recently developed a next-generation affinity-based proteomics technology, termed nELISA. nELISA is a miniaturized ELISA that can be massively multiplexed without suffering from cross-reactivity. The nELISA are performed using barcoded beads and can be read out in high-throughput using common flow cytometry. The nELISA technology has the potential of simultaneously achieving high multiplexing, high-throughput, high-sensitivity while being cost effective.
Achievements/Impact: In this project the team propose to develop a market-ready 150-plex nELISA – the highest ever sandwich immunoassay multiplex – and demonstrate its applicability for cell-based screening. The 150-plex nELISA will be applied to phenotype the secretome in the context of a 5000-compound screen of iPSC-derived astrocytes from a Parkinson’s disease patient. nplex biosciences, a spin-off from McGill University, will commercialize the nELISA, thus making it available to scientists at large.
|$ 1,021,000 / 1 year
|Supported by CQDM through:
|And by co-founding partner: